\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ left\\ costovertebral\\ pain\\ upon\\ palpation\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(478\)\
\-\ ua\\ trace\\ leuko\\ est\\,\\ large\\ blood\\,\\ 30mg\\/dl\\ of\\ protein\\,\\ \\&\\ wbc\\ of\\ 13\\.\ \(0\)\
\-\ ua\\ culture\\ positive\\ for\\ multiple\\ bacterial\\ growth\\ \ \(0\)\
\-\ ldh\\ 377\\ u\\/l\ \(0\)\
\-\ ast\\ \\ 36\\ u\\/l\ \(0\)\
\-\ alt\\ 29\\ u\\/l\ \(0\)\
\-\ afp\\ 0\\.7\\ u\\/l\ \(0\)\
\-\ the\\ pt\\'s\\ pyelonephritis\\ was\\ treated\\ with\\ antibiotics\\ successfully\\.\ \(0\)\
\-\ however\\,\\ the\\ incidental\\ finding\\ of\\ the\\ left\\ lobe\\ hepatic\\ mass\\ was\\ ultrasound\\ guided\\ biopsied\\ that\\ was\\ indeterminate\\ for\\ hepatic\\ adenoma\\,\\ hcc\\,\\ or\\ fnh\\ the\\ pt\\ was\\ sent\\ to\\ surgery\\ for\\ surgical\\ resection\\ of\\ the\\ mass\\.\\ \\ pt\\ improved\\ s\\/p\\ surgery\\ and\\ is\\ doing\\ well\\.\ \(0\)\
\-\ ct\\ findings\\ consistent\\ with\\ acute\\ pyelonephritis\\ involving\\ left\\ kidney\\.\\ \\ a\\ large\\ solid\\ heterogeneously\\ enhancing\\ mass\\ 14\\.1\\ x\\ 9\\.9\\ x\\ 14\\.6\\ cm\\ is\\ seen\\ in\\ the\\ left\\ upper\\ quadrant\\ which\\ is\\ associated\\ with\\ the\\ left\\ lobe\\ of\\ the\\ liver\\ displacing\\ the\\ spleen\\ \\ infra\\-medially\\.\\ \\ some\\ lower\\ attenuating\\ areas\\ near\\ the\\ center\\ of\\ this\\ lesion\\ may\\ represent\\ necrosis\\.\\ \\ no\\ calcification\\ or\\ cystic\\ components\\.\\ \\ prominent\\ vessels\\ are\\ seen\\ at\\ the\\ periphery\\ of\\ the\\ lesion\\ near\\ the\\ left\\ lobe\\ of\\ the\\ liver\\.\\ \\ the\\ remainder\\ of\\ the\\ liver\\ demonstrates\\ multiple\\ round\\ hypoattenuating\\ foci\\ of\\ varying\\ sizes\\,\\ many\\ of\\ which\\ are\\ too\\ small\\ to\\ characterize\\.\\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ mri\\ shows\\ multiple\\ lesions\\ in\\ the\\ liver\\ with\\ the\\ largest\\ in\\ the\\ left\\ lobe\\ with\\ similar\\ imaging\\ appearances\\ as\\ in\\ the\\ ct\\.\ \(0\)\
\-\ hepatic\\ adenoma\ \(5\)\
\-\ hepatocellular\\ adenoma\\ \\(ha\\)\ \(0\)\
\-\ focal\\ nodular\\ hyperplasia\\ \\(fnh\\)\ \(0\)\
\-\ hemangioma\ \(165\)\
\-\ hepatocellular\\ carcinoma\\ \\(hcc\\)\ \(0\)\
\-\ fibrolamellar\\ carcinoma\ \(1\)\
\-\ hepatic\\ metastases\ \(5\)\
\-\ cholangiocarcinoma\ \(16\)\
\-\ liver\\ abscess\ \(5\)\
\-\ 28\\ y\\/o\\ woman\\ with\\ no\\ significant\\ medical\\ hx\\ only\\ taking\\ ocp\\ presented\\ with\\ dysuria\\,\\ polyuria\\,\\ \\&\\ left\\ flank\\ pain\\.\ \(0\)\
\-\ hepatocellular\\ adenomas\\ \\(ha\\)\\ are\\ usually\\ large\\,\\ fatty\\,\\ well\\ circumscribed\\,\\ nonlobulated\\,\\ encapsulated\\ tumors\\.\\ \\ ha\\ are\\ typically\\ solitary\\ in\\ nature\\,\\ but\\ \\~20\\%\\ are\\ multiple\\.\\ \\ they\\ typically\\ do\\ not\\ have\\ bile\\ ducts\\ or\\ portal\\ vein\\ areas\\.\\ \\ they\\ are\\ typically\\ rows\\ of\\ heapatocytes\\.\\ \\ ha\\ can\\ develop\\ central\\ necrosis\\ and\\ hemorrhage\\ because\\ the\\ vascular\\ supply\\ is\\ often\\ restricted\\ to\\ the\\ outer\\ surface\\ of\\ the\\ tumor\\.\\ \\ typically\\ in\\ young\\ woman\\ using\\ oral\\ contraceptives\\ pills\\ \\(ocp\\)\\ ha\\ is\\ one\\ of\\ the\\ more\\ common\\ hepatic\\ neoplasm\\ as\\ in\\ this\\ patient\\.\\ \\ also\\,\\ individuals\\ with\\ hemochromatosis\\ \\,\\ glycogen\\ storage\\ disease\\,\\ acromegaly\\,\\ and\\ anabolic\\ steroids\\ users\\ with\\ a\\ hepatic\\ mass\\ are\\ likely\\ to\\ be\\ ha\\ as\\ well\\.\\ \\ some\\ believe\\ that\\ the\\ ocp\\ \\&\\ anabolic\\ steroids\\ lead\\ to\\ generalized\\ vascular\\ ectasia\\ of\\ the\\ liver\\ leading\\ to\\ the\\ development\\ of\\ ha\\.\\ \\ 80\\%\\ of\\ adenomas\\ are\\ solitary\\ and\\ 20\\%\\ are\\ multiple\\.\ \(0\)\
\-\ computed\\ tomography\\ \\(ct\\)\\ in\\ triple\\ phase\\ liver\\ dedicated\\ study\\ demonstrate\\ most\\ ha\\ as\\ a\\ lesion\\ with\\ homogeneous\\ enhancement\\ in\\ the\\ late\\ arterial\\ phase\\,\\ that\\ will\\ stay\\ isodense\\ to\\ the\\ liver\\ in\\ later\\ phases\\.\\ \\ however\\,\\ these\\ findings\\ in\\ the\\ late\\ arterial\\ phase\\ are\\ not\\ specific\\ to\\ adenomas\\,\\ since\\ hepatocellular\\ carcinoma\\ \\(hcc\\)\\,\\ hemangiomas\\,\\ hypervascular\\ metastases\\,\\ \\&\\ focal\\ nodular\\ hyperplasia\\ \\(fnh\\)\\ can\\ show\\ similar\\ enhancement\\ in\\ the\\ arterial\\ phase\\.\\ \\ the\\ finding\\ of\\ hemorrhage\\ as\\ an\\ area\\ of\\ high\\ attenuation\\ can\\ be\\ seen\\ in\\ as\\ many\\ as\\ 40\\%\\ of\\ adenomas\\.\\ \\ fat\\ deposition\\ within\\ adenomas\\ is\\ often\\ difficult\\ to\\ identify\\ on\\ ct\\ and\\ is\\ better\\ visualized\\ on\\ magnetic\\ resonance\\ imaging\\ \\(mri\\)\\.\ \(0\)\
\-\ due\\ to\\ the\\ risk\\ of\\ intraperitoneal\\ hemorrhage\\ of\\ the\\ ha\\ \\&\\ the\\ rare\\ occurrence\\ of\\ malignant\\ transformation\\ to\\ hcc\\,\\ surgical\\ resection\\ has\\ been\\ advocated\\ as\\ the\\ best\\ solution\\ for\\ patients\\ with\\ presumed\\ ha\\ as\\ was\\ done\\ in\\ this\\ case\\.\\ \\ percutaneous\\ fine\\ needle\\ biopsy\\ of\\ a\\ mass\\ suspicious\\ for\\ ha\\ is\\ controversial\\ because\\ of\\ a\\ significant\\ risk\\ hemorrhage\\ \\&\\ difficult\\ to\\ distinguish\\ from\\ fnh\\ histologically\\ \\(fnh\\ does\\ not\\ require\\ surgical\\ resection\\)\\,\\ however\\,\\ was\\ still\\ performed\\ in\\ this\\ case\\,\\ but\\ diagnosis\\ could\\ not\\ be\\ made\\ from\\ biopsy\\.\\ \\ \\ \\ also\\,\\ ha\\ may\\ also\\ decrease\\ in\\ size\\ if\\ not\\ disappear\\ after\\ ocps\\ have\\ been\\ stopped\\,\\ in\\ this\\ pt\\ the\\ lesion\\ was\\ felt\\ to\\ be\\ too\\ large\\ to\\ pursue\\ this\\ treatment\\.\\ \\ \ \(0\)\
\-\ reference\\:\ \(0\)\
\-\ richard\\ baron\\.\\ \\‚\\Ä\\úliver\\ \\:\\ masses\\ part\\ ii\\ \\:\\ common\\ liver\\ tumors\\‚\\Ä\\ù\\.\\ radiology\\ department\\ of\\ univ\\ of\\ chicago\\.\\ http\\:\\/\\/www\\.radiologyassistant\\.nl\\/en\\/448eef3083354\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ha\\:\\ 0\\.09519593644755332\ \(0\)\
\-\ fnh\\:\\ 0\\.044208182780576095\ \(0\)\
\-\ liver\\:\\ 0\\.04114834512336206\ \(0\)\
\-\ adenomas\\:\\ 0\\.039664973519813886\ \(0\)\
\-\ hcc\\:\\ 0\\.031494215606807555\ \(0\)\
\-\ ocp\\:\\ 0\\.031128033782876846\ \(0\)\
\-\ hepatic\\:\\ 0\\.029903583953681666\ \(0\)\
\-\ u\\/l\\:\\ 0\\.0290759805101803\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.027506693440535596\ \(0\)\
\-\ \\&\\:\\ 0\\.025151295185542724\ \(0\)\
\-\ anabolic\\:\\ 0\\.022688187830744562\ \(0\)\
\-\ phase\\:\\ 0\\.02245658032608803\ \(0\)\
\-\ pt\\:\\ 0\\.01774951818230588\ \(0\)\
\-\ typically\\:\\ 0\\.01685154061176521\ \(0\)\
\-\ are\\:\\ 0\\.016269188163821252\ \(0\)\
\-\ as\\:\\ 0\\.01624748261598764\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.01588970158757562\ \(0\)\
\-\ arterial\\:\\ 0\\.015671834952790523\ \(0\)\
\-\ adenoma\\:\\ 0\\.014951791976840833\ \(0\)\
\-\ pyelonephritis\\:\\ 0\\.013929824099098893\ \(0\)\
\-\ too\\:\\ 0\\.013380354003439522\ \(0\)\
\-\ lobe\\:\\ 0\\.012845393005159408\ \(0\)\
\-\ ua\\:\\ 0\\.012678358393716322\ \(0\)\
\-\ multiple\\:\\ 0\\.012568477677927854\ \(0\)\
\-\ late\\:\\ 0\\.012419191540501332\ \(0\)\
\-\ 30mg\\/dl\\:\\ 0\\.012312176569785612\ \(0\)\
\-\ 377\\:\\ 0\\.012312176569785612\ \(0\)\
\-\ infra\\-medially\\:\\ 0\\.012312176569785612\ \(0\)\
\-\ nonlobulated\\:\\ 0\\.012312176569785612\ \(0\)\
\-\ \\~20\\:\\ 0\\.012312176569785612\ \(0\)\
\-\ heapatocytes\\:\\ 0\\.012312176569785612\ \(0\)\
\-\ baron\\:\\ 0\\.012312176569785612\ \(0\)\
\-\ \\/\\/www\\.radiologyassistant\\.nl\\/en\\/448eef3083354\\:\\ 0\\.012312176569785612\ \(0\)\
\-\ solitary\\:\\ 0\\.011845830853248926\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.011760749268096109\ \(0\)\
\-\ users\\:\\ 0\\.011344093915372281\ \(0\)\
\-\ univ\\:\\ 0\\.011344093915372281\ \(0\)\
\-\ \\,\\:\\ 0\\.011342600510500867\ \(0\)\
\-\ steroids\\:\\ 0\\.011228290163044014\ \(0\)\
\-\ resection\\:\\ 0\\.011165847718660134\ \(0\)\
\-\ \\%\\:\\ 0\\.011135871694670434\ \(0\)\
\-\ 14\\.1\\:\\ 0\\.010777801864941884\ \(0\)\
\-\ chicago\\:\\ 0\\.010777801864941884\ \(0\)\
\-\ left\\:\\ 0\\.010682740438803517\ \(0\)\
\-\ difficult\\:\\ 0\\.010447889968527016\ \(0\)\
\-\ large\\:\\ 0\\.01043878453536916\ \(0\)\
\-\ leuko\\:\\ 0\\.01037601126095895\ \(0\)\
\-\ 14\\.6\\:\\ 0\\.01037601126095895\ \(0\)\
\-\ richard\\:\\ 0\\.01037601126095895\ \(0\)\
\-\ near\\:\\ 0\\.010328281037848445\ \(0\)\
\-\ metastases\\:\\ 0\\.010197576676097721\ \(0\)\
\-\ carcinoma\\:\\ 0\\.010147741634144692\ \(0\)\
\-\ \\(\\:\\ 0\\.010088850925193581\ \(0\)\
\-\ 9\\.9\\:\\ 0\\.010064358256330164\ \(0\)\
\-\ nodular\\:\\ 0\\.010012317896960646\ \(0\)\
\-\ in\\:\\ 0\\.010005241497743483\ \(0\)\
\-\ however\\:\\ 0\\.009969419227362027\ \(0\)\
\-\ \\)\\:\\ 0\\.00996561022504616\ \(0\)\
\-\ many\\:\\ 0\\.009810652279071012\ \(0\)\
\-\ rows\\:\\ 0\\.009809719210528553\ \(0\)\
\-\ advocated\\:\\ 0\\.009809719210528553\ \(0\)\
\-\ lesion\\:\\ 0\\.009723772212293043\ \(0\)\
\-\ was\\:\\ 0\\.009661931083094703\ \(0\)\
\-\ polyuria\\:\\ 0\\.009594424964959755\ \(0\)\
\-\ glycogen\\:\\ 0\\.009594424964959755\ \(0\)\
\-\ disappear\\:\\ 0\\.009594424964959755\ \(0\)\
\-\ ocps\\:\\ 0\\.009594424964959755\ \(0\)\
\-\ necrosis\\:\\ 0\\.009422069031968449\ \(0\)\
\-\ contraceptives\\:\\ 0\\.009407928606545617\ \(0\)\
\-\ similar\\:\\ 0\\.009362253125533208\ \(0\)\
\-\ est\\:\\ 0\\.009243427160098154\ \(0\)\
\-\ acromegaly\\:\\ 0\\.009243427160098154\ \(0\)\
\-\ costovertebral\\:\\ 0\\.009096275601916833\ \(0\)\
\-\ pursue\\:\\ 0\\.009096275601916833\ \(0\)\
\-\ tumors\\:\\ 0\\.0089656881499176\ \(0\)\
\-\ solution\\:\\ 0\\.00896316082565381\ \(0\)\
\-\ attenuating\\:\\ 0\\.00884163655611522\ \(0\)\
\-\ characterize\\:\\ 0\\.00884163655611522\ \(0\)\
\-\ appearances\\:\\ 0\\.008729845064951064\ \(0\)\
\-\ pills\\:\\ 0\\.008729845064951064\ \(0\)\
\-\ risk\\:\\ 0\\.008645828623908064\ \(0\)\
\-\ fibrolamellar\\:\\ 0\\.008626342310546424\ \(0\)\
\-\ storage\\:\\ 0\\.008626342310546424\ \(0\)\
\-\ believe\\:\\ 0\\.008626342310546424\ \(0\)\
\-\ not\\:\\ 0\\.008623035417192285\ \(0\)\
\-\ they\\:\\ 0\\.008600408174545549\ \(0\)\
\-\ encapsulated\\:\\ 0\\.008529983551486436\ \(0\)\
\-\ dedicated\\:\\ 0\\.008529983551486436\ \(0\)\
\-\ biopsy\\:\\ 0\\.008468416876080338\ \(0\)\
\-\ histologically\\:\\ 0\\.008439845952132286\ \(0\)\
\-\ indeterminate\\:\\ 0\\.008355174692612126\ \(0\)\
\-\ because\\:\\ 0\\.008350609822866057\ \(0\)\
\-\ to\\:\\ 0\\.008350493740505317\ \(0\)\
\-\ mass\\:\\ 0\\.008299308707734388\ \(0\)\
\-\ hemochromatosis\\:\\ 0\\.008275344505684824\ \(0\)\
\-\ 13\\.\\:\\ 0\\.008128192947503502\ \(0\)\
\-\ biopsied\\:\\ 0\\.008128192947503502\ \(0\)\
\-\ can\\:\\ 0\\.008121043376267052\ \(0\)\
\-\ well\\:\\ 0\\.00809950119958932\ \(0\)\
\-\ 0\\.7\\:\\ 0\\.008060050260116027\ \(0\)\
\-\ hypoattenuating\\:\\ 0\\.008060050260116027\ \(0\)\
\-\ triple\\:\\ 0\\.008060050260116027\ \(0\)\
\-\ this\\:\\ 0\\.008054222457939662\ \(0\)\
\-\ areas\\:\\ 0\\.008031696009067226\ \(0\)\
\-\ displacing\\:\\ 0\\.007932994703962777\ \(0\)\
\-\ x\\:\\ 0\\.00787448697024435\ \(0\)\
\-\ trace\\:\\ 0\\.007873553901701889\ \(0\)\
\-\ vascular\\:\\ 0\\.007826266111518706\ \(0\)\
\-\ sizes\\:\\ 0\\.007816539942874717\ \(0\)\
\-\ phases\\:\\ 0\\.007816539942874717\ \(0\)\
\-\ occurrence\\:\\ 0\\.007816539942874717\ \(0\)\
\-\ controversial\\:\\ 0\\.007816539942874717\ \(0\)\
\-\ dysuria\\:\\ 0\\.007761762410537732\ \(0\)\
\-\ ectasia\\:\\ 0\\.007709052455254426\ \(0\)\
\-\ finding\\:\\ 0\\.0076929092319510655\ \(0\)\
\-\ often\\:\\ 0\\.007615847900892884\ \(0\)\
\-\ stay\\:\\ 0\\.007561900897073104\ \(0\)\
\-\ isodense\\:\\ 0\\.007561900897073104\ \(0\)\
\-\ stopped\\:\\ 0\\.007561900897073104\ \(0\)\
\-\ surgical\\:\\ 0\\.00752606886976866\ \(0\)\
\-\ cholangiocarcinoma\\:\\ 0\\.007516105055141553\ \(0\)\
\-\ ldh\\:\\ 0\\.007471763297718955\ \(0\)\
\-\ hemangiomas\\:\\ 0\\.00742878612081008\ \(0\)\
\-\ be\\:\\ 0\\.007361769404156029\ \(0\)\
\-\ afp\\:\\ 0\\.007346606651504308\ \(0\)\
\-\ guided\\:\\ 0\\.007268995127545075\ \(0\)\
\-\ distinguish\\:\\ 0\\.007268995127545075\ \(0\)\
\-\ some\\:\\ 0\\.007248402943761897\ \(0\)\
\-\ successfully\\:\\ 0\\.007231748972402393\ \(0\)\
\-\ the\\:\\ 0\\.007144166946975076\ \(0\)\
\-\ identify\\:\\ 0\\.007125623403997473\ \(0\)\
\-\ doing\\:\\ 0\\.007091967605702695\ \(0\)\
\-\ intraperitoneal\\:\\ 0\\.007091967605702695\ \(0\)\
\-\ seen\\:\\ 0\\.00707525537039535\ \(0\)\
\-\ hypervascular\\:\\ 0\\.0070591037825041\ \(0\)\
\-\ also\\:\\ 0\\.007058461984651472\ \(0\)\
\-\ heterogeneously\\:\\ 0\\.0070269955168271465\ \(0\)\
\-\ varying\\:\\ 0\\.006995608846642708\ \(0\)\
\-\ resonance\\:\\ 0\\.006995608846642708\ \(0\)\
\-\ individuals\\:\\ 0\\.006964912049549446\ \(0\)\
\-\ fine\\:\\ 0\\.006876673360133899\ \(0\)\
\-\ ducts\\:\\ 0\\.0068484572884613855\ \(0\)\
\-\ magnetic\\:\\ 0\\.0068484572884613855\ \(0\)\
\-\ focal\\:\\ 0\\.006817021240610062\ \(0\)\
\-\ largest\\:\\ 0\\.006767076131863655\ \(0\)\
\-\ transformation\\:\\ 0\\.006767076131863655\ \(0\)\
\-\ presumed\\:\\ 0\\.006767076131863655\ \(0\)\
\-\ ct\\:\\ 0\\.006677674041296329\ \(0\)\
\-\ periphery\\:\\ 0\\.006665456921971995\ \(0\)\
\-\ deposition\\:\\ 0\\.006665456921971995\ \(0\)\
\-\ supply\\:\\ 0\\.006641166778519664\ \(0\)\
\-\ been\\:\\ 0\\.006493840473363104\ \(0\)\
\-\ ast\\:\\ 0\\.006482026751495616\ \(0\)\
\-\ alt\\:\\ 0\\.006482026751495616\ \(0\)\
\-\ spleen\\:\\ 0\\.006419009383785463\ \(0\)\
\-\ reference\\:\\ 0\\.006419009383785463\ \(0\)\
\-\ significant\\:\\ 0\\.0064185674610453165\ \(0\)\
\-\ enhancement\\:\\ 0\\.006398013313192838\ \(0\)\
\-\ bile\\:\\ 0\\.006378523997090976\ \(0\)\
\-\ tomography\\:\\ 0\\.006378523997090976\ \(0\)\
\-\ culture\\:\\ 0\\.006358713054364781\ \(0\)\
\-\ taking\\:\\ 0\\.006339179196858161\ \(0\)\
\-\ outer\\:\\ 0\\.006339179196858161\ \(0\)\
\-\ percutaneous\\:\\ 0\\.0063199147804722175\ \(0\)\
\-\ \\:\\:\\ 0\\.006314384446875224\ \(0\)\
\-\ computed\\:\\ 0\\.0063009124731317435\ \(0\)\
\-\ is\\:\\ 0\\.006282578529438276\ \(0\)\
\-\ portal\\:\\ 0\\.006282165238030989\ \(0\)\
\-\ common\\:\\ 0\\.006246556457978763\ \(0\)\
\-\ generalized\\:\\ 0\\.006245409220827953\ \(0\)\
\-\ 29\\:\\ 0\\.006227387705694004\ \(0\)\
\-\ fatty\\:\\ 0\\.006192027638676838\ \(0\)\
\-\ that\\:\\ 0\\.006184276795637528\ \(0\)\
\-\ better\\:\\ 0\\.006157540749584141\ \(0\)\
\-\ protein\\:\\ 0\\.006123884951289364\ \(0\)\
\-\ bacterial\\:\\ 0\\.006107356379156679\ \(0\)\
\-\ sent\\:\\ 0\\.006074874728089266\ \(0\)\
\-\ needle\\:\\ 0\\.006074874728089266\ \(0\)\
\-\ 36\\:\\ 0\\.005981730350297824\ \(0\)\
\-\ develop\\:\\ 0\\.005952013313360276\ \(0\)\
\-\ hx\\:\\ 0\\.005908590705720567\ \(0\)\
\-\ center\\:\\ 0\\.005852717333355065\ \(0\)\
\-\ components\\:\\ 0\\.005852717333355065\ \(0\)\
\-\ surgery\\:\\ 0\\.005796086771956075\ \(0\)\
\-\ part\\:\\ 0\\.005785879314950547\ \(0\)\
\-\ suspicious\\:\\ 0\\.005747259857785031\ \(0\)\
\-\ lead\\:\\ 0\\.00572209434730643\ \(0\)\
\-\ leading\\:\\ 0\\.005709679616276757\ \(0\)\
\-\ improved\\:\\ 0\\.00568517639050733\ \(0\)\
\-\ still\\:\\ 0\\.00568517639050733\ \(0\)\
\-\ nature\\:\\ 0\\.005649209217179935\ \(0\)\
\-\ homogeneous\\:\\ 0\\.005649209217179935\ \(0\)\
\-\ remainder\\:\\ 0\\.005625735588246443\ \(0\)\
\-\ 28\\:\\ 0\\.005625735588246443\ \(0\)\
\-\ flank\\:\\ 0\\.005614145081522007\ \(0\)\
\-\ 80\\:\\ 0\\.005614145081522007\ \(0\)\
\-\ felt\\:\\ 0\\.005614145081522007\ \(0\)\
\-\ imaging\\:\\ 0\\.005592384984512856\ \(0\)\
\-\ woman\\:\\ 0\\.0055136953840472245\ \(0\)\
\-\ restricted\\:\\ 0\\.005492620811983418\ \(0\)\
\-\ mri\\:\\ 0\\.0054840107679179325\ \(0\)\
\-\ require\\:\\ 0\\.0054612341417989785\ \(0\)\
\-\ decrease\\:\\ 0\\.0054612341417989785\ \(0\)\
\-\ department\\:\\ 0\\.0053518321260588855\ \(0\)\
\-\ hemangioma\\:\\ 0\\.005332829818718412\ \(0\)\
\-\ circumscribed\\:\\ 0\\.005304802496021751\ \(0\)\
\-\ surface\\:\\ 0\\.005268286741686105\ \(0\)\
\-\ represent\\:\\ 0\\.005241513115837334\ \(0\)\
\-\ may\\:\\ 0\\.005235554103067385\ \(0\)\
\-\ case\\:\\ 0\\.005222079421416958\ \(0\)\
\-\ young\\:\\ 0\\.005198000311675609\ \(0\)\
\-\ development\\:\\ 0\\.005198000311675609\ \(0\)\
\-\ growth\\:\\ 0\\.00518945809517081\ \(0\)\
\-\ do\\:\\ 0\\.0051809678073546335\ \(0\)\
\-\ using\\:\\ 0\\.0051809678073546335\ \(0\)\
\-\ have\\:\\ 0\\.005168821447947184\ \(0\)\
\-\ round\\:\\ 0\\.0051558022968760326\ \(0\)\
\-\ ii\\:\\ 0\\.005147513560116515\ \(0\)\
\-\ foci\\:\\ 0\\.005122938473677437\ \(0\)\
\-\ for\\:\\ 0\\.005091537350856949\ \(0\)\
\-\ but\\:\\ 0\\.0050907913436691\ \(0\)\
\-\ findings\\:\\ 0\\.005080550099971955\ \(0\)\
\-\ radiology\\:\\ 0\\.0050440108057118755\ \(0\)\
\-\ oral\\:\\ 0\\.005028746740722783\ \(0\)\
\-\ 40\\:\\ 0\\.005021176814089628\ \(0\)\
\-\ best\\:\\ 0\\.005021176814089628\ \(0\)\
\-\ s\\/p\\:\\ 0\\.005006158948480323\ \(0\)\
\-\ done\\:\\ 0\\.0049476520466518875\ \(0\)\
\-\ specific\\:\\ 0\\.004933400412330321\ \(0\)\
\-\ prominent\\:\\ 0\\.0048983948695046\ \(0\)\
\-\ upon\\:\\ 0\\.004877805090542025\ \(0\)\
\-\ visualized\\:\\ 0\\.004830910823036991\ \(0\)\
\-\ vessels\\:\\ 0\\.004804804492014432\ \(0\)\
\-\ attenuation\\:\\ 0\\.004798353450315696\ \(0\)\
\-\ solid\\:\\ 0\\.004760260687858072\ \(0\)\
\-\ made\\:\\ 0\\.004754011692893099\ \(0\)\
\-\ rare\\:\\ 0\\.004634567316582816\ \(0\)\
\-\ incidental\\:\\ 0\\.004519257818408206\ \(0\)\
\-\ http\\:\\ 0\\.004519257818408206\ \(0\)\
\-\ antibiotics\\:\\ 0\\.0044828440749588\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.00445740351645134\ \(0\)\
\-\ which\\:\\ 0\\.004455711137549019\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.004432418090821766\ \(0\)\
\-\ could\\:\\ 0\\.004403013888031498\ \(0\)\
\-\ of\\:\\ 0\\.004393299750762134\ \(0\)\
\-\ since\\:\\ 0\\.004383749471645554\ \(0\)\
\-\ wbc\\:\\ 0\\.004350663199128229\ \(0\)\
\-\ calcification\\:\\ 0\\.0043321028190742026\ \(0\)\
\-\ vein\\:\\ 0\\.004318342628511337\ \(0\)\
\-\ malignant\\:\\ 0\\.004313785860864946\ \(0\)\
\-\ later\\:\\ 0\\.00430924391200129\ \(0\)\
\-\ 20\\:\\ 0\\.004291222396867341\ \(0\)\
\-\ kidney\\:\\ 0\\.004204446166270964\ \(0\)\
\-\ quadrant\\:\\ 0\\.004200245717857618\ \(0\)\
\-\ or\\:\\ 0\\.004196324367166372\ \(0\)\
\-\ involving\\:\\ 0\\.0041877196424627006\ \(0\)\
\-\ does\\:\\ 0\\.004072096467016769\ \(0\)\
\-\ neoplasm\\:\\ 0\\.004064464491497106\ \(0\)\
\-\ masses\\:\\ 0\\.0040343469245755405\ \(0\)\
\-\ size\\:\\ 0\\.004001223284048563\ \(0\)\
\-\ palpation\\:\\ 0\\.00398315514015091\ \(0\)\
\-\ central\\:\\ 0\\.00392685943695525\ \(0\)\
\-\ study\\:\\ 0\\.00392685943695525\ \(0\)\
\-\ positive\\:\\ 0\\.003872745237826979\ \(0\)\
\-\ abscess\\:\\ 0\\.003773514307450094\ \(0\)\
\-\ area\\:\\ 0\\.003773514307450094\ \(0\)\
\-\ enhancing\\:\\ 0\\.0037429518615708928\ \(0\)\
\-\ will\\:\\ 0\\.003733912036842377\ \(0\)\
\-\ medical\\:\\ 0\\.003672220391153637\ \(0\)\
\-\ show\\:\\ 0\\.00366362560683188\ \(0\)\
\-\ fat\\:\\ 0\\.0036297658140804936\ \(0\)\
\-\ usually\\:\\ 0\\.0036242014718809485\ \(0\)\
\-\ only\\:\\ 0\\.003588563768833709\ \(0\)\
\-\ treated\\:\\ 0\\.0035724173688322057\ \(0\)\
\-\ ultrasound\\:\\ 0\\.0035406740014054514\ \(0\)\
\-\ from\\:\\ 0\\.0035375299250117666\ \(0\)\
\-\ cystic\\:\\ 0\\.0034422244514689363\ \(0\)\
\-\ likely\\:\\ 0\\.0033663267680665594\ \(0\)\
\-\ performed\\:\\ 0\\.0033276233676359204\ \(0\)\
\-\ y\\/o\\:\\ 0\\.0033053478070106715\ \(0\)\
\-\ shows\\:\\ 0\\.0032812481839788812\ \(0\)\
\-\ high\\:\\ 0\\.0032661257836268374\ \(0\)\
\-\ blood\\:\\ 0\\.0032575573638398037\ \(0\)\
\-\ presented\\:\\ 0\\.003253292786344147\ \(0\)\
\-\ if\\:\\ 0\\.0032384684829338483\ \(0\)\
\-\ one\\:\\ 0\\.003234261708534419\ \(0\)\
\-\ cm\\:\\ 0\\.0032010560304706506\ \(0\)\
\-\ lesions\\:\\ 0\\.003194916908301603\ \(0\)\
\-\ due\\:\\ 0\\.003184744627029106\ \(0\)\
\-\ these\\:\\ 0\\.0031059283407232404\ \(0\)\
\-\ patients\\:\\ 0\\.003088791339896684\ \(0\)\
\-\ more\\:\\ 0\\.002984883113564478\ \(0\)\
\-\ acute\\:\\ 0\\.002946758839534211\ \(0\)\
\-\ physical\\:\\ 0\\.002928079985448657\ \(0\)\
\-\ consistent\\:\\ 0\\.0029263942302111775\ \(0\)\
\-\ pain\\:\\ 0\\.002915106613214343\ \(0\)\
\-\ upper\\:\\ 0\\.0028800007058222324\ \(0\)\
\-\ associated\\:\\ 0\\.0028162884942844997\ \(0\)\
\-\ tumor\\:\\ 0\\.0027824473486184513\ \(0\)\
\-\ a\\:\\ 0\\.0027695516886773832\ \(0\)\
\-\ most\\:\\ 0\\.002755356343195637\ \(0\)\
\-\ small\\:\\ 0\\.002749406821761339\ \(0\)\
\-\ demonstrate\\:\\ 0\\.0027464415381746377\ \(0\)\
\-\ diagnosis\\:\\ 0\\.002740529791592765\ \(0\)\
\-\ lower\\:\\ 0\\.002684164901346177\ \(0\)\
\-\ \\'s\\:\\ 0\\.0026313500256522977\ \(0\)\
\-\ exam\\:\\ 0\\.0026218351116613662\ \(0\)\
\-\ demonstrates\\:\\ 0\\.0026070128514709304\ \(0\)\
\-\ after\\:\\ 0\\.002469275422638551\ \(0\)\
\-\ treatment\\:\\ 0\\.0024156661446939763\ \(0\)\
\-\ no\\:\\ 0\\.0024034752812955363\ \(0\)\
\-\ within\\:\\ 0\\.0022767198441146393\ \(0\)\
\-\ has\\:\\ 0\\.0022412010761093267\ \(0\)\
\-\ on\\:\\ 0\\.002022041933981643\ \(0\)\
\-\ disease\\:\\ 0\\.001950750755887855\ \(0\)\
\-\ with\\:\\ 0\\.0017975501913251215\ \(0\)\
\-\ an\\:\\ 0\\.001650369922185377\ \(0\)\
\-\ at\\:\\ 0\\.0016169876436195993\ \(0\)\
\-\ \\.\\:\\ 0\\.001536991088013596\ \(0\)\
\-\ and\\:\\ 0\\.0012570461294149331\ \(0\)\
\-\ patient\\:\\ 0\\.0011963574454139498\ \(0\)\
